Compugen Ltd.
NASDAQ:CGENBiotechnology
+$0.01 today
- Market cap
- $185.66M
- Beta
- 2.74
- P/E (TTM)
- 5.4
- EPS (TTM)
- $0.37
Volume 0.15M
Average 0.48M
CGEN Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Compugen Ltd.NASDAQ: CGEN
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 67.0% from a year ago
Total equity stood at $95.35M at the end of Q1 FY2026, up 67.0% from a year earlier and down 7.2% from the prior quarter. Over 3 fiscal years it compounded at +9.8% a year.
Context
- Total equity amounted to 65.4% of total assets at the end of Q1 FY2026, up 15.9 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +67.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 102.73M USD
- Year-over-year change
- +87.1%
- 4-year CAGR
- -0.9%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 102.73M | +87.1% |
| FY2024 | 2024-12-31 | 54.91M | -16.2% |
| FY2023 | 2023-12-31 | 65.56M | -15.6% |
| FY2022 | 2022-12-31 | 77.68M | -27.2% |
| FY2021 | 2021-12-31 | 106.69M | — |
Total Equity vs competitors
How CGEN compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +67.0% is the 3rd highest of 9, against a peer median of -16.4%.
- Total equity amounts to 65.4% of total assets for CGEN, versus a peer median of 69.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $227.14M USD | +25.9% | +5.8% | 88.1% | |
| Mar 2026 | $126.34M USD | -0.6% | +64.7% | 87.4% | |
| Mar 2026 | $95.35M USD | +67.0% | +9.8% | 65.4% | |
| Mar 2026 | CHF 68.25M CHF | -46.8% | -30.1% | 78.1% | |
| Mar 2026 | $36.05M USD | +688.7% | -14.3% | 18.6% | |
| Mar 2026 | $35.54M USD | +764.5% | -17.5% | 68.5% | |
| Mar 2026 | $34.71M USD | -51.0% | -24.7% | 70.6% | |
| Mar 2026 | $14.22M USD | -32.1% | +9.0% | 56.0% | |
| Dec 2025 | -€21.69M EUR | -345.6% | — | 34.6% | |
| Peer median (excluding CGEN) | — | -16.4% | -14.3% | 69.5% | |
Competitors are the stored peer set for CGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 7.8M | 11.06M | 13.89M | 18.23M | 90.6M |
| Short-term Investments | 109.25M | 72.29M | 36.8M | 85.03M | 55.04M |
| Net Receivables | 188K | 317K | 61.32M | 269K | 294K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 713K | 362K | 365K | 0 | 0 |
| Total Current Assets | 123.22M | 86.13M | 114.58M | 106M | 148.02M |
| Property, Plant & Equipment (Net) | 3.91M | 3.36M | 2.55M | 3.7M | 3.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 410K |
| Tax Assets | 0 | 0 | 0 | 0 | 303K |
| Other Non-current Assets | 5.04M | 4.69M | 4.21M | 5.3M | 4.94M |
| Total Non-current Assets | 8.94M | 8.05M | 6.76M | 9M | 8.85M |
| Total Assets | 132.16M | 94.18M | 121.33M | 115M | 156.87M |
| Account Payables | 4.62M | 1.77M | 3.5M | 1.84M | 2.35M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 11.15M | 9.63M | 10.97M |
| Other Current Liabilities | 6.93M | 3.14M | 3.13M | 3.07M | 3.05M |
| Total Current Liabilities | 17.1M | 11.92M | 26.27M | 20.16M | 22.57M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 303K |
| Deferred Revenue (Non-current) | 0 | 0 | 25.39M | 34.05M | 24.94M |
| Other Non-current Liabilities | 6.39M | 3.27M | 3.4M | 3.41M | 3.89M |
| Total Non-current Liabilities | 8.37M | 4.58M | 29.51M | 39.92M | 31.57M |
| Total Liabilities | 25.47M | 16.5M | 55.78M | 60.08M | 54.14M |
| Common Stock | 239K | 240K | 247K | 248K | 262K |
| Retained Earnings | (422.08M) | (455.77M) | (474.53M) | (488.76M) | (453.42M) |
| Accumulated OCI | 0 | 0 | 2K | 11K | 8K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 106.69M | 77.68M | 65.56M | 54.91M | 102.73M |
| Total Debt | 2.75M | 1.93M | 1.35M | 2.91M | 2.96M |
| Net Debt | (5.05M) | (9.13M) | (12.54M) | (15.32M) | (87.64M) |
Compugen Ltd.
NASDAQ:CGEN
Intrinsic Alpha fair value
Locked
Current Price
$1.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.